Employer file: Medpace, where the financials and the reviews disagree

Medpace is the most interesting employer file in the CRO group, because its two report cards point in opposite directions. On the financial scorecard it is a fast-growing, profitable, distinctive company. On the employee scorecard it is the lowest-rated major CRO by a clear margin. Both are true, and the gap between them is the story.

The facts

Medpace is headquartered in Cincinnati and trades on the Nasdaq. It was founded in 1992 by August Troendle, a physician and former FDA medical reviewer, who remains chairman and CEO more than 30 years on, which makes it distinctly founder-led in an industry of private-equity portfolios and merged conglomerates. It employs roughly 6,300 people, and headcount has grown steadily, up about 16 percent from 2023, with no layoff signal in the numbers.

Its model is genuinely different. Rather than subcontracting heavily, Medpace runs a vertically integrated, full-service operation with its own central lab, imaging core lab, bioanalytical lab, and a Phase I unit co-located on its Cincinnati campus, which it has been expanding. That integration is a real competitive asset and a real differentiator from the badged-and-outsourced model much of the industry runs on.

The sentiment

Now the other report card, and it should be read as sentiment: self-selected anonymous reviews, not a measurement of the company. On Glassdoor, scraped in July 2026, Medpace carried about 3.0 out of 5, with only 41 percent of reviewers recommending it and 22 percent approving of the CEO, the lowest marks of any major CRO in the group. The recurring complaints cluster tightly: high turnover attributed to low pay, bonuses described as hard to reach, criticism of upper management, and a near-absence of remote work in an industry that largely went hybrid. The category scores for work-life balance and senior management sit near the bottom.

Treat those numbers with the usual caution. Reviews skew toward the disgruntled, and a demanding, founder-led culture tends to generate polarized sentiment. But the consistency of the low-pay and low-flexibility themes, across a decent number of reviews, is a pattern worth weighing rather than dismissing.

Reading the gap

Put the two report cards together and a coherent picture emerges. Medpace's own recent results showed the fastest revenue growth in the CRO group alongside a book-to-bill that fell below 1.0, a sign its forward bookings softened even as its current numbers impressed. Pair that with employee reviews centered on pay and intensity, and you get the profile of a lean-run, founder-driven, financially disciplined company: efficient and growing, which the market rewards, and demanding on the people inside, which the reviews reflect. Neither report card is the whole truth. Together they sketch the trade a Medpace job might involve.

What no report card can tell you

The financials show growth; the reviews show sentiment. Neither tells you what a specific role at Medpace actually pays, whether the low-pay complaints hold at your level and function, or whether the intensity is worth it for the experience. Those are the questions the public data cannot answer, and they live only with the people who work there. If you are at Medpace or left recently, your real number and your real experience are worth more to the next candidate than any star rating. Add your datapoint to the survey.